Back to Search Start Over

Use of liposomal amphotericin B in disseminated cutaneous leishmaniasis caused by Leishmania braziliensis in a pediatric patient with Down syndrome.

Authors :
Sandoval-Juárez A
Rojas-Palomino N
Roca LK
Pilares-Barco G
Cuadros-Castro J
Araujo-Castillo R
Source :
Revista peruana de medicina experimental y salud publica [Rev Peru Med Exp Salud Publica] 2023 Jan-Mar; Vol. 40 (1), pp. 94-98. Date of Electronic Publication: 2023 Jun 23.
Publication Year :
2023

Abstract

We present a case of disseminated cutaneous leishmaniasis with extensive manifestation in a pediatric patient with Down syndrome. The case was confirmed by parasitological and immunological tests. The species was identified as Leishmania (Viannia) braziliensis by polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP). The immune deficit that occurs as part of Down syndrome may have been the reason for the aggressive and prolonged clinical manifestations as well as the poor response to stibogluconate and deoxycholate amphotericin. The patient was treated with liposomal amphotericin B and at the end of therapy, showed clinical improvement of the lesions. This report highlights the challenges of the diagnosis and treatment of cutaneous leishmaniasis in immunosuppressed pediatric patients, especially under difficult social, economic and geographic conditions. Leishmaniasis should be considered as a differential diagnosis when treating atypical chronic dermatologic ulcers; the use of liposomal amphotericin in immunocompromised patients should also be considered in these cases.

Details

Language :
Spanish; Castilian; English
ISSN :
1726-4642
Volume :
40
Issue :
1
Database :
MEDLINE
Journal :
Revista peruana de medicina experimental y salud publica
Publication Type :
Report
Accession number :
37377243
Full Text :
https://doi.org/10.17843/rpmesp.2023.401.11481